Rising clinical recognition of extravascular hemolysis (EVH) in C5-treated PNH patients, expanding approval of proximal C3 and Factor B/D inhibitors, and continuous biopharma innovation are driving therapeutic shifts across the Paroxysmal Nocturnal Hemoglobinuria Market. While C5 inhibition halts terminal intravascular lysis, residual C3 opsonization can cause C3b-mediated extravascular...